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Abstract In a recent placebo-controlled study inmild atopic asthmatics, we observed a significant decrease in eosi-
nophilsinthebronchial submucosa, after 2monthsoftreatmentwithinhaled formoterolandbudesonide.Biopsymaterial
from each treatment group; formoterol (24 mg bid), budesonide (400 mg b.i.d.) and placebo has been further assessed
toinvestigatetherole of Th-2 cytokinesbyimmunohistochemistryusingMabs to eosinophils as anindexof inflammation,
IL-4 and IL-5.Treatment with formoterol significantly reduced the number of eosinophils (EG2+) in the submucosa and
epithelium, butthiswas not paralleled bychanges in cytokine immunoreactivity.In contrast, treatmentwith budesonide
significantly reduced both the number of eosinophils (EG2+) and immunoreactivity for IL-4 and IL-5 in the submucosa.
Thus, whilebudesonidehas effects oncytokinesinvolvedineosinophilrecruitmentthis explanationdoesnot apply tothe
eosinopaenia observed with the long-acting b2 adrenoreceptor agonist formoterol. r 2002 Elsevier Science Ltd. All rights
reserved.
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Inmany types of asthma, theTh-2 likeT-lymphocytes or-
chestrate the recruitment, migration and activation of
eosinophils and mast cells in the airway wall by the se-
cretion of cytokines encoded in the interleukin (IL)-4
gene cluster, speci¢cally IL-3, IL-4, IL-5, IL-9, IL-13 and
granulocyte macrophage colony stimulating factor
(GM-CSF) (1^3). Both oral and inhaled corticosteroids
reduce the in£ux, activation and survival of in£amma-
tory cells in the airway wall by reducing the production
of Th-2 cytokines (4,5).Formoterol by inhalation is a po-
tent andhighly selective b2-adrenoreceptor agonist (6,7)
with rapid onset and prolonged duration of action of at
least 12h (8,9). Asthma management guidelines recom-
mend that the long-acting b2 adrenoreceptor-agonists,
formoterol and salmeterol, can be given twice daily to
supplement inhaled corticosteroids when these drugs at
moderate to high doses fail to control asthma (10). Addi-
tion of these long-acting b2-adrenoreceptor agonists im-
proves symptoms and lung function (11) reduces asthmaReceived 8 April 2002 and accepted in revised form 29 April 2001.
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E-mail: annika.wallin@lung.umu.se.exacerbations (12,13) and enhances asthma-related qual-
ity of life (14) beyond that achieved by further increasing
the dose of inhaled corticosteroid.While part of this re-
sponsemaybe explained by the bronchodilator action of
this drug class, it has also been shown that they inhibit
eosinophil activation (15), IL-8 and eotaxin release (16,17),
microvascular leakage (18) and in£ux of in£ammatory
cells (19,20).
In an earlier study, investigating the e¡ects of 8 weeks
treatment of asthmatic subjectswith inhaled formoterol
and budesonide, we reported a signi¢cant decrease
in eosinophils present in the airways (20). The
present study was designed to explore thepotentialme-
chanisms that could account for the eosinopaenia
observed with both the drugs. Speci¢cally, we have
tested the hypothesis that ‘‘formoterol mediates its




Bronchial biopsies were collected from 30 non-smoking,
atopic mild asthmatic subjects with a FEV1470% of pre-
dicted, airway hyperresponsiveness de¢ned as a provo-
1022 RESPIRATORYMEDICINEcative concentration of methacholine required to reduce
FEV1 by 20% of baseline (PC20 methacholine) 40.1 and
o6mg/ml, who required only as required b2 agonist over
the preceding 2 months (Table1). Selection was based on
the availabilityof tissue.Of the 64 subjects evaluated in the
original study (20), a subgroup of 30,10 in each treatment
groupwere selected for analysis.With a sample size of10 in
each group and assuming that 80% of the patients on ac-
tive treatmentcompared to10% onplacebowill improve, a
two-sided Fisher’s exact test with a 0.05 signi¢cance level
will have at least 80% power to detect a di¡erence.
Study design
This was a parallel group, double-blind placebo-con-
trolled study comparing the e¡ects of 8-week treatment
with formoterol 24mg, budesonide 400mg or placebo
twice dailyon airway in£ammation accessedby bronchial
biopsies performed before and at the end of the treat-
ment period.The Ethics Committee of the University of
Ume. approved the study and each patient gave in-
formedwritten consent.
Fiberoptic bronchoscopy
Bronchoscopy was conducted using standard proce-
dures conforming to NHLBIGuidelines (21,22). Pre-med-
ication consisted of atropine (0.5^1.0mg) s.c., nebulized
salbutamol (2.5mg) and ipratropium bromide (500mg).
At each bronchoscopy, 4^6 endobronchial biopsies were
taken as previously described (20).
Biopsy processing and
immunohistochemical analysis
Bronchial mucosal biopsies were ¢xed overnight at
201C in acetone-containing protease inhibitors and
then processed into glycol methacrylate (GMA) (23).
Twomicrometer sectionswere cut and stained immuno-
histochemically using the streptavidin^biotin peroxi-
dase detection system. Monoclonal antibodies (Mabs)
directed to eosinophils (EG2, PharmaciaUp John, Milton





FEV1, % predicted 9479
PC20 methacholine (mg/ml) 1.0572.34
Themean71SDis shown for age and FEV1% of predicted, andcytokines IL-4 (3H4 and 4D9, AMS Biotechnology,
Abingdon,U.K.) and IL-5 (MAB 7,Glaxo Smith Kline, Mid-
dlesex,U.K. (gift)) were employed.Negative control sec-
tions were incubated with isotype-matched
immunoglobulins. Following staining, the samples were
blinded for treatment group, and the number of EG2
and cytokine positive cells permm2 submucosawere en-
umerated with the assistance of computerised image
analysis (Improvision, Birmingham,U.K.).
Data analysis
Non-parametric tests were used, the WilcoxonŁ s Rank-
sum test for within and the Mann^Whitney U-test for
between treatment analyses. Data are given as median
and the 25^75% interquartile range, unless otherwise
stated. A P value ofo0.05 was considered signi¢cant.
RESULTS
Bronchial biopsies
Table 2 summarises information on immunohistochem-
ical staining in the epithelium and submucosa before and
after the placebo, formoterol and budesonide treat-
ments. Formoterol treatment signi¢cantly reduced the
number of eosinophils (EG2+) in the submucosa com-
pared to pre-treatmentvalues (P=0.005).Thiswas signif-
icant compared to placebo (P=0.04), but not
budesonide. Eight weeks formoterol treatment had no
within group or between group e¡ects on the number
of cells immunoreactive for IL-5 or stored (4D9) and se-
creted (3H4) IL-4.Budesonide treatment signi¢cantly re-
duced the number of eosinophils (P =0.02) in the
submucosa.This was paralleled by a signi¢cant decrease
in cells staining for stored IL-4 (4D9 P=0.008) and IL-5
(P=0.03).The change in eosinophils was signi¢cant com-
pared to placebo (P=0.02), but not formoterol.
DISCUSSION
Our prior observation that treatmentofmild asthmatics








geometricmean71SD for PC20 methacholine.
TABLE 2. Summaryof immunohistochemical data
Treatment
Formoterol Placebo Budesonide
Marker Pre Post Pre Post Pre Post
Eosinophils 21.1 3.9a,b 6.1 2.8 2.4 0a
(17.1^28.7) (1.2^9.7) (0.6^10.5) (0.4^5.2) (0.4^5.2) (0^0.6)
IL-4 (3H4) 13.4 8.7 17.7 20.4 8.8 7.3
(9.8^18.0) (6.7^10.9) (7.5^28.6) (12.7^23.8) (5.7^24.2) (4.6^11.1)
IL-4 (4D9) 2.8 0.7 2.5 2.8 5.1 1.3a
(0.4^4.8) (0^1.8) (1.2^4.7) (0.9^5.7) (3.4^9.9) (0.1^2.4)
IL-5 1.4 0.9 2.2 1.0 3.1 0a
(0.6^1.8) (0.2^1.2) (0^3.0) (0.6^1.4) (0.4^4.4) (0^0.5)
All data aremediannumbercells (25^75 percentiles) permm2 of submucosa.
asigni¢cantwithin group changespre-andpost-treatment
bsigni¢cant betweengroup di¡erences: formoterolvs.placebo.
EFFECTSOFREGULARINHALEDFORMOTEROLANDBUDESONIDE 1023resulted in a reduction in the airway eosinophilia de-
served explanation since this e¡ect may contribute to
its therapeutic e⁄cacy.Wehavepreviously foundno sup-
port for thehypothesis thatNF-kB regulatedexpression
of the cytokines IL-8,GM-CSF and tumour necrosis fac-
tor-a (TNFa) or endothelial adhesionmoleculeswere in-
volved (24).To address the possible involvement of Th-2,
cytokines,we assessed the level of expression of IL-4 and
IL-5. Budesonide and placebo were included as positive
and negative controls against which to compare the re-
ponse to formoterol. Despite showing a 81% decrease in
submucosal eosinophils, formoterol had no discernable
e¡ect on Il-4 or IL-5 which contrasted with the inhibi-
tory e¡ects that budesonide, but not placebo had on
these markers. Thus, while con¢rming the potent anti-
in£ammatory action of an inhaled steroid this study has
failed to incriminate inhibition of IL-4 or IL-5 production
as being responsible for the tissue eosinopaenia.
In the present study, 8 weeks of treatment with bude-
sonide had a powerful e¡ect in reducing airway eosino-
phils which is in agreement with our earlier observation
(20) and thatof others (4,25).Thereduction in eosinophils
is probably inpart theresultof a loss of cells that store IL-
4 and IL-5 or a selective loss of theirTh-2 cytokine con-
tent within the submucosa together with the adhesion
molecule vascular adhesion molecule-1 (VCAM-1), as we
have previously reported (24). IL-4 and IL-5 are key cyto-
kines in eosinophil-mediated disease (reviewed in 26). In
combination with TNFa, IL-4 speci¢cally enhances and
stabilises the expression of VCAM-1on endothelial cells,
an adhesion molecule that plays an important role in eo-
sinophil recruitment by interacting with the integrin
CD49d expressed on circulating eosinophils. IL-4 is also a
chemoattractant for primed eosinophils. IL-5 is a key eo-
sinophilopoietic cytokine, which stimulates their devel-
opment, enhances their maturation, and primes themfordegranulation andchemotaxis,whilsthaving a chemo-
tactic activity itself. In addition, IL-5 inhibits eosinophil
apoptosis thereby enhancing survival.The importance of
IL-4 and IL-5 is highlighted in two recent studies in symp-
tomatic asthmatics (27,28). Soluble IL-4 receptor which
binds to free IL-4 has been shown to be therapeutically
e¡ective (27) and a blocking humanised antibody against
IL-5 has a profound e¡ect in reducing both peripheral
blood and airways eosinophils (28). A decrease in stored
IL-4 and IL-5 after inhaled corticosteroid treatment has
been reportedby other workers (4).
Although in this present study, we have con¢rmed the
e¡ect of 8 weeks inhaled formoterol on eosinophils as
shown in our previous study (20), we could not ¢nd any
evidence for the mechanism of action. Several alterna-
tive mechanisms could be involved. Important for the
chemotaxis/recruitment of eosinophils are the chemo-
kines eotaxin and RANTES together with leukotrienes.
Eotaxin is a speci¢c chemokine for eosinophils that to-
gether with IL-5 is important for their recruitment, sur-
vival and activation (26). RANTES and eotaxin interact
with eosinophils through the chemokine receptor
(CCR-3) whose expression is high on eosinophils (26).
Eotaxin is regulated by NF-kB, whose activation in the
epitheliumwehaverecentlydemonstrated tobereduced
by formoterol compared to placebo (24). In vitro studies
have shown that b2-adrenoreceptor agonists can inhibit
cytokine-induced eotaxin release from cultured human
smoothmuscle cells (17). AnotherNF-kB regulatedpath-
way that maybe involved is the cysteinyl leukotrienes
andnitric oxide (NO),mediatorswhich can in£uence eo-
sinophil recruitment (29^31).
An alternative pathway is an e¡ect of formoterol on
eosinophil apoptosis. The survival of eosinophils is af-
fected by IL-3, IL-5 and GM-CSF (26), involving both FAS
antigen and p38 MAP kinase (32,33). FAS has been found
1024 RESPIRATORYMEDICINEto induce eosinophil apoptosis, and FAS antibodies to in-
hibit in vitro and in vivo survival of the eosinophils (34).
Formoterolmay also have a direct e¡ect on eosinophil
recruitment. In a guinea pig cutaneous in£ammatory
model, salmeterol has been shown to directly inhibit the
accumulation of eosinophils. The exact mechanism for
this is not known, but one suggestion is that decreased
CD18 expression on the surface of the eosinophils, an in-
tegrin, that is necessary for itsmigration into tissue (35).
In conclusion; 8weeks treatmentwith inhaledbudeso-
nide and formoterol in mild allergic asthmatic subjects
reduces eosinophil cell numbers. For budesonide, but
not formoterol treatment, this was paralleledwith a de-
crease in Th-2 cytokines. However, the mechanism of
formoterol action on eosinopaenia still needs elucida-
tion.
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